Answers are grounded in this paper and cite their sources.
Losartan, a commonly prescribed US Food and Drug Administration-approved medication for hypertension, demonstrated clinical improvement and amelioration of fibrosis in the dy(2J) /dy(2J) mouse model of MDC1A via TGF-β and MAPK signaling pathways. The results of this study support pursuing a clinical trial of losartan treatment in children with MDC1A.
No takes yet. Share an insight, caveat, or question.
Elbaz et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: